

ASX Announcement Extension of Closing Date of the Non-Renounceable Entitlement Offer

SYDNEY 16 AUGUST 2023 - Allegra Orthopaedics Limited (Allegra) (ASX: AMT) wishes to advise that it has resolved to extend the closing date for the 1 for 3 non-renounceable entitlement offer (Entitlement Offer).

On 19 July 2023, the Company announced a non-renounceable entitlement offer of up to 34,819,735 (subject to rounding) new fully paid ordinary shares (Shares) at an issue price of \$0.09 per Share on the basis of one (1) Share for every three (3) Shares held at the Record Date to raise up to \$3,133,776.

The Company advises that the closing date of the Rights Issue to eligible shareholders has been extended to Monday, 28 August 2023 5:00pm AEST (Closing Date). The Closing Date has been extended to allow eligible Shareholders more time to participate in the Entitlement Offer.

The revised timetable for the Rights Issue is shown below. These events and dates are indicative only and subject to change. Subject to the ASX Listing Rules, the Corporations Act 2001 (Cth) and other applicable laws, the Company's Board reserves the right to modify all dates, including the Entitlement Offer closing date.

Action	Date
Closing Date (5.00pm AEST)*	5.00pm (AEST) on Monday, 28 August 2023
Shares quoted on a deferred settlement basis	Tuesday, 29 August 2023
Announcement of results of Entitlement Offer and under- subscriptions	Wednesday, 30 August 2023
Issue of Offer Shares under the Entitlement Offer and lodgement of Appendix 2A with ASX applying for quotation of the Shares	Monday, 4 September 2023

^{*}The Directors may extend the Closing Date by giving at least 3 Business Days' notice to ASX prior to the Closing Date. Accordingly, the date the Shares are expected to commence trading on ASX may vary.

Eligible shareholders should consider the Pro Rata Non-Renounceable Entitlement Offer Booklet (Offer Document) dated 19 July 2023 in deciding whether to acquire securities under the Entitlement Offer and are required to follow the instructions on the Entitlement and Acceptance Form which accompanies the Offer Document.

This announcement has been authorised for release by the Board of Directors of Allegra.

Allegra Orthopaedics Limited

Level 8, 18 --- 20 Orion Rd, Lane Cove West NSW 2066 Australia; PO Box 72 St Leonards NSW 2065 Australia

T+612 9119 9200 T Toll Free 1800 644 370

F+612 9439 4441 F Toll Free 1800 624 223

E sales@allegraorthopaedics.com



Contact details:

Robyn Slaughter Company Secretary T: +61 2 8072 1435

ABOUT ALLEGRA ORTHOPAEDICS:

We aim to help bring the freedom and happiness of pain-free movement to people's lives. We achieve this through providing the best possible solutions for patients, from world-wide industry leading orthopaedic products through to Australian innovations. Allegra's principal product, the Active Total Knee, has significantly improved the quality of life for many people and remains a focused product line. Allegra is also the exclusive distributor of Waldemar Link GmbH & Co. KG products in Australia. Link consists of a range of complex lower limb, hip and knee replacements, including oncology solutions. The Link products add to Allegra's well-developed range of products for distribution from international suppliers covering all specialties from foot and ankle to upper limb. The company is pleased to continue to build upon its extensive portfolio of patents. It has strong research relationships with universities, companies and surgeon inventors.